Keywords: Otsuka, Lundbeck, Abilify Maintena, USA, FDA, Schizophrenia, Once-monthly

FDA approves Otsuka and Lundbeck's once-monthly Abilify Maintena for schizophrenia

Article | 01 March 2013

Print This

Japanese drugmaker Otsuka Pharmaceutical (TYO: 4578) and Danish partner Lundbeck (LUND: DC) have received approval from the US Food and Drug ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in